The PLD inhibitor attenuated colitis-associated CRC and orthotopically injected tumors, probably by controlling multiple pathways, including Wnt signaling, phagocytosis checkpoints, and immune signaling. This evidence concerns the gene GPLD1 and colorectal carcinoma.